Previous close | 0.1500 |
Open | N/A |
Bid | 0.0000 |
Ask | 0.4500 |
Strike | 0.50 |
Expiry date | 2024-12-20 |
Day's range | 0.1500 - 0.1500 |
Contract range | N/A |
Volume | |
Open interest | 1 |
Adaptimmune's (ADAP) shares plummet as the company;s collaboration to develop and commercialize allogeneic cell therapies with Roche gets terminated.
Adaptimmune Therapeutics ( NASDAQ:ADAP ) Full Year 2023 Results Key Financial Results Revenue: US$60.3m (up 122% from...
Key Financial Highlights and Business Updates